Here’s what you should know.
1. Senator Chuck Grassley (R-Iowa) said the senator is requesting documents from Mylan and the Centers for Medicare and Medicaid Services about the warnings CMS issued the company about its incorrect classification of the EpiPen.
2. Mylan classified its drug as a generic and is only paying Medicaid a 13 percent rebate. However, CMS contends it is a brand-name drug and it should be paying 23 percent.
3. Sen. Grassley was joined by Senators Amy Klobuchar (D-Minn.) and Richard Blumenthal (D-Conn.) in his inquiry.
4. CMS confirmed to the senator that Mylan misclassified the drug.
5. Sen. Blumenthal said the misclassification shows “criminal intent.”
6. A Mylan representative said the drug was properly classified and in accordance with government guidance.
More coding, billing and collections news:
5 things to know about the new healthcare scam linked to the ACA
Auditors claim Obama administration illegally distributed payments to payers under ACA reinsurance program — 5 key points
Minnesota asks 45k to reapply for coverage after computer error: 4 things to know
